Xomed
This article was originally published in The Gray Sheet
Executive Summary
Three-for-two stock split is effective Nov. 16. The additional shares will be distributed on Nov. 30 through a stock dividend of one additional common share for every two shares of Xomed stock held. "The stock split is designed to provide a trading price range that is accessible to a broader group of investors," Xomed explains. Third-quarter 1998 results announced in conjunction with the split show a 17.5% sales increase to $21.9 mil. Net income is up 62% to $2.2 mil. The company's flagship XPS model 2000 StraightShot power resection system, used in least invasive endoscopic sinus surgery as well as certain head and neck procedures "continues to receive strong market acceptance with a global installed base of over 1,500 units at the end of the third quarter," the firm reports
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.